Stockscreener 앱 받기
12.65
4.03%
0.49
시간 외 거래:
12.69
0.04
+0.32%
전일 마감가:
$12.16
열려 있는:
$11.72
하루 거래량:
470.25K
Relative Volume:
1.01
시가총액:
$620.48M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+11.16%
1개월 성능:
-4.46%
6개월 성능:
-43.73%
1년 성능:
+0.00%
1일 변동 폭
$11.41
$13.31
1주일 범위
$10.55
$13.31
52주 변동 폭
$8.91
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
명칭
Bicara Therapeutics Inc
전화
617-785-8308
주소
245 MAIN STREET, CAMBRIDGE
BCAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
12.65 | 620.48M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-17 | 개시 | Wells Fargo | Underweight |
| 2025-02-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
| 2024-10-08 | 개시 | Stifel | Buy |
| 2024-10-08 | 개시 | TD Cowen | Buy |
모두보기
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
Bicara Stock: Innovative Precision Tumor Targeting (NASDAQ:BCAX) - Seeking Alpha
Wells Fargo & Company Initiates Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Vanguard Group Inc. Acquires 1,020,528 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Wells Fargo Initiates Coverage of Bicara Therapeutics (BCAX) with Underweight Recommendation - Nasdaq
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Bicara Therapeutics initiated with an Underweight at Wells Fargo - TipRanks
Wells Fargo Initiates Bicara Therapeutics at Underweight With $8 Price Target - marketscreener.com
Corebridge Financial Inc. Takes $167,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
HC Wainwright Issues Pessimistic Forecast for BCAX Earnings - Defense World
Promising Developments and Market Opportunities Drive Buy Rating for Bicara Therapeutics - TipRanks
HC Wainwright Issues Pessimistic Forecast for Bicara Therapeutics (NASDAQ:BCAX) Stock Price - The AM Reporter
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $36.67 Average Target Price from Brokerages - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Given New $44.00 Price Target at HC Wainwright - Defense World
Bicara stock price target lowered to $44 at H.C. Wainwright By Investing.com - Investing.com Canada
Bicara stock price target lowered to $44 at H.C. Wainwright - Investing.com
Buy Rating Affirmed for Bicara Therapeutics Inc. Amid Promising Clinical Data and Financial Stability - TipRanks
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 3.2%Should You Sell? - MarketBeat
FY2025 EPS Estimates for BCAX Raised by Cantor Fitzgerald - Defense World
Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock - Investing.com
Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock By Investing.com - Investing.com UK
Promising Data and Durable Responses Drive Buy Rating for Bicara Therapeutics - TipRanks
Q1 EPS Estimate for Bicara Therapeutics Reduced by Analyst - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Earns Outperform Rating from Wedbush - Defense World
Charles Schwab Investment Management Inc. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Stifel raises Bicara stock price target to $48, maintains Buy By Investing.com - Investing.com Canada
Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Progress and Strong Financial Position - TipRanks
Bicara Therapeutics Reports Strong Financial Position and Clinical Progress - TipRanks
Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı
Stifel raises Bicara stock price target to $48, maintains Buy - Investing.com India
Bank of New York Mellon Corp Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc QTRLY Loss Per Share $0.39 - MarketScreener
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ... - Enid News & Eagle
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 - The Manila Times
Skandinaviska Enskilda Banken AB publ Purchases Shares of 38,035 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Bicara Therapeutics Inc (BCAX): A New Perspective - Stocks Register
Cantor Fitzgerald Reiterates “Overweight” Rating for Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $41.20 Consensus Price Target from Analysts - Defense World
Cantor Fitzgerald maintains Overweight on Bicara Therapeutics By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains Overweight on Bicara Therapeutics - Investing.com India
Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth - Yahoo Finance
19,008 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Rhumbline Advisers - Defense World
Bicara Therapeutics Inc.’s (NASDAQ:BCAX) Lock-Up Period Set To Expire on March 12th - Defense World
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Bicara Therapeutics Inc (BCAX) 재무 분석
Bicara Therapeutics Inc (BCAX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):